Company registration number 08858643 (England and Wales)
BIOARCHITECH LTD
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2026
PAGES FOR FILING WITH REGISTRAR
BIOARCHITECH LTD
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 8
BIOARCHITECH LTD
BALANCE SHEET
AS AT 31 JULY 2026
31 July 2026
- 1 -
2026
2025
Notes
£
£
£
£
Fixed assets
Intangible assets
4
5,970
3,900
Tangible assets
5
12,408
15,842
18,378
19,742
Current assets
Debtors
6
118,541
156,388
Cash at bank and in hand
622,083
270,826
740,624
427,214
Creditors: amounts falling due within one year
7
(6,564)
(17,550)
Net current assets
734,060
409,664
Net assets
752,438
429,406
Capital and reserves
Called up share capital
9
1,422
1,319
Share premium account
3,368,494
2,593,719
Other reserves
55,001
51,293
Profit and loss reserves
(2,672,479)
(2,216,925)
Total equity
752,438
429,406

For the financial year ended 31 July 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 19 October 2026 and are signed on its behalf by:
Dr G Hale
Director
Company registration number 08858643 (England and Wales)
BIOARCHITECH LTD
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 JULY 2026
- 2 -
Share capital
Share premium account
Other reserves
Profit and loss reserves
Total
Notes
£
£
£
£
£
Balance at 1 August 2024
1,319
2,593,719
46,171
(1,706,269)
934,940
Year ended 31 July 2025:
Loss and total comprehensive income
-
-
-
(510,656)
(510,656)
Share based payments
8
-
-
5,122
-
0
5,122
Balance at 31 July 2025
1,319
2,593,719
51,293
(2,216,925)
429,406
Year ended 31 July 2026:
Loss and total comprehensive income
-
-
-
(455,554)
(455,554)
Issue of share capital
9
103
774,775
-
-
774,878
Share based payments
8
-
-
3,708
-
0
3,708
Balance at 31 July 2026
1,422
3,368,494
55,001
(2,672,479)
752,438
BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JULY 2026
- 3 -
1
Accounting policies
Company information

Bioarchitech Ltd is a private company limited by shares incorporated in England and Wales. The registered office is 64 Arlington Drive, Marston, Oxford, OX3 0SJ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Research and development expenditure

Research and development expenditure is written off against profits in the year in which it is incurred.

1.4
Intangible fixed assets other than goodwill

Intangible assets acquired separately from a business are recognised at cost and are subsequently measured at cost less accumulated amortisation and accumulated impairment losses.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Trademarks, patents and licences
10 years straight line
1.5
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold improvements
Straight line over lease term
Plant and machinery
25% straight line
Fixtures, fittings & equipment
25% straight line
Computer equipment
33.33% straight line
1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2026
1
Accounting policies
(Continued)
- 4 -
1.7
Cash and cash equivalents

Cash at bank and in hand are basic financial assets and include cash in bank only.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include other debtors, corporation tax recoverable and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including trade creditors, and other creditors, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs.

BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2026
1
Accounting policies
(Continued)
- 5 -
1.10
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

1.11
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

1.12
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.13
Share-based payments

Equity-settled share-based payments are measured at fair value at the date of grant by reference to the fair value of the equity instruments granted using the Black-Scholes model. The fair value determined at the grant date is expensed on a straight-line basis over the vesting period, based on the estimate of shares that will eventually vest. A corresponding adjustment is made to equity.

1.14
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2026
2025
Number
Number
Total
4
4
3
Directors' remuneration
2026
2025
£
£
Remuneration paid to directors
72,942
69,643
BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2026
- 6 -
4
Intangible fixed assets
Trademarks, patents and licences
£
Cost
At 1 August 2025
3,900
Additions
5,970
Disposals
(3,900)
At 31 July 2026
5,970
Amortisation and impairment
At 1 August 2025 and 31 July 2026
-
0
Carrying amount
At 31 July 2026
5,970
At 31 July 2025
3,900
5
Tangible fixed assets
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 August 2025
18,600
104,225
122,825
Additions
-
0
2,958
2,958
At 31 July 2026
18,600
107,183
125,783
Depreciation and impairment
At 1 August 2025
18,600
88,383
106,983
Depreciation charged in the year
-
0
6,392
6,392
At 31 July 2026
18,600
94,775
113,375
Carrying amount
At 31 July 2026
-
0
12,408
12,408
At 31 July 2025
-
0
15,842
15,842
6
Debtors
2026
2025
Amounts falling due within one year:
£
£
Corporation tax recoverable
96,250
107,865
Other debtors
22,291
48,523
118,541
156,388
BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2026
- 7 -
7
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
1,939
13,051
Other creditors
4,625
4,499
6,564
17,550
8
Share-based payment transactions
Number of share options
Weighted average exercise price
2026
2025
2026
2025
Number
Number
£
£
Outstanding at 1 August 2025
30,000
30,000
2.80
2.80
Granted
21,000
-
0
2.80
-
0
Outstanding at 31 July 2026
51,000
30,000
2.80
2.80
Exercisable at 31 July 2026
32,000
30,000
2.80
2.80

The options outstanding at 31 July 2026 had an exercise price of £2.80 and an average remaining contractual life of 7.24 years.

Inputs were as follows:
2026
2025
Weighted average share price
2.80
2.80
Weighted average exercise price
2.80
2.80
Expected volatility
50.00
50.00
Expected life
10.00
10.00
Risk free rate
2.96
1.89

During the year, the company recognised total share-based payment expenses of £3,708 (2025: £5,122) which related to equity settled share based payment transactions.

 

9
Called up share capital
2026
2025
2026
2025
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of 0.1p each
1,421,638
1,318,321
1,422
1,319

During the year, the company issued 103,317 Ordinary 0.1p shares for a total consideration of £774,878.

BIOARCHITECH LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JULY 2026
- 8 -
10
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2026
2025
£
£
Total commitments
43,826
66,614
2026-07-312025-08-01falsefalsefalse19 October 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityDr G HaleMr K Maskell088586432025-08-012026-07-31088586432026-07-31088586432025-07-3108858643core:PatentsTrademarksLicencesConcessionsSimilar2026-07-3108858643core:PatentsTrademarksLicencesConcessionsSimilar2025-07-3108858643core:LandBuildings2026-07-3108858643core:OtherPropertyPlantEquipment2026-07-3108858643core:LandBuildings2025-07-3108858643core:OtherPropertyPlantEquipment2025-07-3108858643core:CurrentFinancialInstrumentscore:WithinOneYear2026-07-3108858643core:CurrentFinancialInstrumentscore:WithinOneYear2025-07-3108858643core:CurrentFinancialInstruments2026-07-3108858643core:CurrentFinancialInstruments2025-07-3108858643core:ShareCapital2026-07-3108858643core:ShareCapital2025-07-3108858643core:SharePremium2026-07-3108858643core:SharePremium2025-07-3108858643core:OtherMiscellaneousReserve2026-07-3108858643core:OtherMiscellaneousReserve2025-07-3108858643core:RetainedEarningsAccumulatedLosses2026-07-3108858643core:RetainedEarningsAccumulatedLosses2025-07-3108858643core:ShareCapital2024-07-3108858643core:SharePremium2024-07-3108858643core:RetainedEarningsAccumulatedLosses2024-07-3108858643core:ShareCapitalOrdinaryShareClass12026-07-3108858643core:ShareCapitalOrdinaryShareClass12025-07-3108858643bus:Director12025-08-012026-07-3108858643core:RetainedEarningsAccumulatedLosses2024-08-012025-07-31088586432024-08-012025-07-3108858643core:RetainedEarningsAccumulatedLosses2025-08-012026-07-3108858643core:ShareCapital2025-08-012026-07-3108858643core:SharePremium2025-08-012026-07-3108858643core:IntangibleAssetsOtherThanGoodwill2025-08-012026-07-3108858643core:PatentsTrademarksLicencesConcessionsSimilar2025-08-012026-07-3108858643core:LeaseholdImprovements2025-08-012026-07-3108858643core:PlantMachinery2025-08-012026-07-3108858643core:FurnitureFittings2025-08-012026-07-3108858643core:ComputerEquipment2025-08-012026-07-3108858643core:PatentsTrademarksLicencesConcessionsSimilar2025-07-3108858643core:PatentsTrademarksLicencesConcessionsSimilarcore:ExternallyAcquiredIntangibleAssets2025-08-012026-07-3108858643core:LandBuildings2025-07-3108858643core:OtherPropertyPlantEquipment2025-07-31088586432025-07-3108858643core:LandBuildings2025-08-012026-07-3108858643core:OtherPropertyPlantEquipment2025-08-012026-07-31088586432024-07-3108858643bus:OrdinaryShareClass12025-08-012026-07-3108858643bus:OrdinaryShareClass12026-07-3108858643bus:OrdinaryShareClass12025-07-3108858643bus:PrivateLimitedCompanyLtd2025-08-012026-07-3108858643bus:SmallCompaniesRegimeForAccounts2025-08-012026-07-3108858643bus:FRS1022025-08-012026-07-3108858643bus:AuditExemptWithAccountantsReport2025-08-012026-07-3108858643bus:Director22025-08-012026-07-3108858643bus:FullAccounts2025-08-012026-07-31xbrli:purexbrli:sharesiso4217:GBP